Senator Says FDA Will Limit Abortion Drug if More Deaths Reported

National   |   Steven Ertelt   |   Nov 29, 2005   |   9:00AM   |   WASHINGTON, DC

Senator Says FDA Will Limit Abortion Drug if More Deaths Reported Email this article
Printer friendly page

by Steven Ertelt
LifeNews.com Editor
November 29, 2005

Washington, DC (LifeNews.com) — A leading pro-life member of the U.S. Senate says he’s been told by Food and Drug Administration officials that the agency may limit sales of the RU 486 abortion drug if they find more women have died from using it. The drug has already been responsible for the deaths of four California women.

Sen. Jim DeMint, a South Carolina Republican, says the FDA told him it would curb sales of the drug if it finds more deaths during its investigation into how and why the four women died. The agency is expected to meet with officials from the Centers for Disease Control earlier next year to discuss the problem.

"Increasingly, they are aware that it is a dangerous drug," DeMint said in an interview with the Baltimore Sun. He has been in contact with the agency since the summer, urging it to suspend sales of the drug.

Of the chances that the FDA will halt sales, he said, "I’m very hopeful."

The Baltimore Sun newspaper reported that FDA officials would not say whether they have met with DeMint or any other lawmakers about restricting access to the drug. However, DeMint said he met with former FDA Commissioner Dr. Lester M. Crawford over the summer and has spoken with other official since.

The FDA in July issued a warning to doctors to watch out for signs of sepsis or other infections and noted that normal telltale signs may not appear until it’s too late.

The agency updated its strong black box warning in November after it discovered that all four California women were infected by Clostridium sordellii, a rare and deadly bacterium.

Observers suspect the infections may have occurred because Planned Parenthood abortion businesses instruct women to use the first of the two-part abortion drug vaginally instead of orally as the FDA recommends.